Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 1, 2025
Clene to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the …
Cannabix Technologies to Attend U.S. National Drug and Alcohol Conference to Market Marijuana Breath Test
GlobeNewswire
·
April 1, 2025
VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it will …
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
GlobeNewswire
·
April 1, 2025
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates …
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
GlobeNewswire
·
April 1, 2025
SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat …
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
GlobeNewswire
·
April 1, 2025
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of action This investigational treatment was …
Unity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended Immunizations
GlobeNewswire
·
April 1, 2025
AIAW 2025 Runs April 7-11 to Encourage Well-Visits and Recommended Immunizations VENTNOR CITY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- UNITY® Consortium, a non-profit dedicated to adolescent and young adult immunization and preventive health, urges …
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
GlobeNewswire
·
April 1, 2025
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) -- Clearmind …
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
GlobeNewswire
·
April 1, 2025
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. The …
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 1, 2025
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in EuropeOperating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focusBERKELEY, Calif. and MAINZ, Germany, …
Nkarta to Participate in an April Investor Conference
GlobeNewswire
·
April 1, 2025
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th …
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
GlobeNewswire
·
April 1, 2025
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
GlobeNewswire
·
April 1, 2025
NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Phathom Pharmaceuticals Announces Leadership Succession
GlobeNewswire
·
April 1, 2025
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven …
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
GlobeNewswire
·
April 1, 2025
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced …
electroCore to Participate at the Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place …
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
GlobeNewswire
·
April 1, 2025
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
GlobeNewswire
·
April 1, 2025
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the …
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire’s management team will host a corresponding …
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
FeraMAXᴹᴰ est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis dix années consécutives
GlobeNewswire
·
April 1, 2025
MISSISSAUGA, Ontario, 01 avr. 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer la plus recommandée au Canada selon un sondage pancanadien …